Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: a multicenter pooled analysis in Taiwan | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: a multicenter pooled analysis in Taiwan

Chiu WN, Hung CH, Lu SN, et al. Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: a multicenter pooled analysis in Taiwan. J Viral Hepat. 2020;27(9):866-872.

Publication Type:

Journal Article

Authors:

Chiu, WN; Hung, CH; Lu, SN; et, al

Source:

J Viral Hepat, Volume 27, Issue 9, p.866-872 (2020)

Cited On:

Initial Treatment of Adults with HCV Infection

External Third-party Web Link:

https://onlinelibrary.wiley.com/doi/abs/10.1111/jvh.13305

Export Citation:

RIS Format

Top